Can Ultrasound-Guided biopsies improve breast cancer diagnosis in nigeria?
NCT ID NCT04501419
First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
This study tests whether training Nigerian radiologists in ultrasound-guided breast biopsy can improve the accuracy of breast cancer diagnosis. Women with suspicious breast masses will receive this biopsy method instead of the usual blind biopsy or surgical excision. Researchers will compare the biopsy results to surgical pathology to measure accuracy and complication rates.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ultrasound-guided breast biopsy procedure and a training program for radiologists
- What this could lead to
- If successful, this approach could make accurate breast cancer diagnosis more accessible in Nigeria and other low-resource settings.
- What could go wrong
- The study is early and depends on training effectiveness; results may not generalize beyond the participating hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2019
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 and older female * Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis. Exclusion Criteria: * Participants unwilling to sign consent * Participants under the age of 18.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC)
RECRUITINGIle-Ife, Nigeria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?